Clinicopathological features    
Total number of cases 200 %
Gender Males 128 64%
  Female 72 36%
Stage CP-CML 81 40.50%
  AP-CML 54 27%
  BC-CML 65 32.50%
BCR-ABL type a2b2 59 29.50%
  a2b3 124 62%
  a2b2/ a2b3 17 8.50%
Therapy Imatinib 200  
Age group Age >45 71 35.50%
  Age <45 129 64.50%
Molecular response MMR 50 25%
  No MR 150 75%
Haematological response MHR 30 15%
  Minor HR 46 23%
  Loss HR 124 62%
Thrombocytopenia   100 50%
Table 3: Clinical pathological features of CML patients.